Skip to main content
[Preprint]. 2021 Mar 1:2021.03.01.433110. [Version 1] doi: 10.1101/2021.03.01.433110

Figure 5. Immunogenicity of LCB1v1.3 and protection from challenge.

Figure 5.

(A) Scheme of experimental details. K18-hACE2 transgenic mice (n = 10 to 12 per group) were treated every 3 days with 50 μg of LCB1v1.3 or control binder by i.n. administration. On day 18 post-treatment, animals were bled and anti-LCB1v1.3 antibodies were measured. The following day, animals were challenged with 103 PFU of SARS-CoV-2, and tissues were collected at 7 dpi. (B) Binding of serum antibodies to LCB1v1.3 as measured by ELISA (three experiments). Dashed line indicated limit of detection of the assay. (C) Weight change following LCB1v1.3 or control binder administration (mean ± SEM; two experiments: two-way ANOVA with Sidak’s post-test: **** P < 0.0001). (D-H) Viral RNA levels at 7 dpi in the lung, heart, spleen, brain, or nasal wash (two experiments: Mann-Whitney test: * P < 0.05, ** P < 0.01, **** P < 0.0001).